Low Dose Naltrexone for Weight Loss: What the Evidence Actually Shows
Low dose naltrexone, often called LDN, is frequently discussed online as a possible weight loss tool. Here’s a more grounded look at what the evidence supports, what remains uncertain, and where it may fit into a broader treatment plan.
Key takeaways
Low dose naltrexone refers to naltrexone used at much smaller doses than its standard FDA-approved form, usually around 0.5 to 4.5mg instead of 50mg.
Its use for weight loss is off-label and not FDA-approved. Current evidence remains limited and largely preliminary.
Some clinicians explore LDN as part of a broader metabolic or appetite-focused plan, but it is not considered a first-line weight loss treatment.
If you are considering LDN, the safest approach is to review it with a licensed provider who can assess your goals, medications, and medical history.
What is naltrexone, and what does “low dose” mean?
Naltrexone is a medication that blocks opioid receptors. At its standard 50mg dose, it is FDA-approved for opioid use disorder and alcohol use disorder.
Low dose naltrexone uses a much smaller amount, typically around 1 to 4.5mg. At these doses, it is thought to briefly block opioid receptors and then potentially trigger rebound effects in endogenous opioid signaling, though the clinical significance of that remains under investigation.
The proposed mechanisms for weight effects
Inflammation modulation
One theory is that LDN may help reduce certain inflammatory signals that can affect metabolic health. This idea is still being studied and is not yet clearly established for weight loss outcomes.
Appetite and reward pathways
Because opioid signaling is involved in reward and food-related behavior, some believe LDN may help reduce reward-driven eating in select patients. This remains a proposed mechanism rather than a proven effect.
Gut-brain interactions
There is early discussion around possible gut and microbiome-related effects, but this area is still speculative and far from definitive.
What the current evidence supports
The current evidence for LDN as a standalone weight loss treatment is limited. Most of the discussion comes from small studies, clinician experience, and anecdotal reports rather than large randomized clinical trials.
The stronger evidence in this area involves bupropion and naltrexone together in the FDA-approved medication Contrave. That is a different treatment model and uses naltrexone differently than typical low dose protocols.
Where LDN may fit in practice
Some providers may consider LDN in more individualized cases, especially when someone is not tolerating other options well or when weight concerns overlap with appetite regulation, inflammation, or other broader symptoms.
That said, LDN should not be framed as a proven shortcut for weight loss. If it is used, it is usually part of a more comprehensive plan that may also include nutrition changes, movement, sleep support, and in some cases other prescription therapies.
Is LDN worth exploring?
For some people, it may be worth discussing with a qualified provider. It is generally considered low cost and is often well tolerated, but that does not automatically mean it is effective for every patient or appropriate for every goal.
The best next step is an individualized medical discussion that looks at expected benefit, medication interactions, and whether more evidence-based weight loss options may be a better fit.
† This article is for educational purposes only and does not constitute medical advice. Low dose naltrexone for weight loss is an off-label use and is not FDA-approved for that purpose.